Evidence map›Paper›PMID 30067752›Full record

ArticlePloS one2018

Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting.

Padmapriyadarsini Chandrasekaran, Vidya Mave, Kannan Thiruvengadam, Nikhil Gupte, Shri Vijay Bala Yogendra Shivakumar, Luke Elizabeth Hanna, Vandana Kulkarni, Dileep Kadam, Kavitha Dhanasekaran, Mandar Paradkar and 12 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. LTBI Prevalence and Risk Factors in Field Practice Areas of a Tertiary Care Hospital, Jodhpur, Rajasthan.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  15. Article
  16. BCG vaccination induced protection from COVID-19.The Indian journal of tuberculosis · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Padmapriyadarsini ChandrasekaranDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-1324-4595
Vidya MaveJohns Hopkins University School of Medicine, Baltimore, United States of America.
Kannan ThiruvengadamDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Nikhil GupteJohns Hopkins University School of Medicine, Baltimore, United States of America.
Shri Vijay Bala Yogendra ShivakumarJohns Hopkins University-India office, Pune, India.
Luke Elizabeth HannaDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Vandana KulkarniByramjee- Jeejeebhoy Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India.ORCID 0000-0002-3488-2692
Dileep KadamDepartment of Medicine, Byramjee Jeejeebhoy Government Medical College, Pune, India.
Kavitha DhanasekaranDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Mandar ParadkarByramjee- Jeejeebhoy Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India.
Beena ThomasDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Rewa KohliByramjee- Jeejeebhoy Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India.
Chandrakumar DollaDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Renu BharadwajDepartment of Medicine, Byramjee Jeejeebhoy Government Medical College, Pune, India.
Gomathi Narayan SivaramakrishnanDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Neeta PradhanByramjee- Jeejeebhoy Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India.
Akshay GupteJohns Hopkins Bloomberg School of Public Health, Baltimore, United States of America.
Lakshmi MuraliDepartment of Chest Medicine, Government Headquarters Hospital, Thiruvallur, India.
Chhaya ValviDepartment of Medicine, Byramjee Jeejeebhoy Government Medical College, Pune, India.
Soumya SwaminathanIndian Council of Medical Research, New Delhi, India.
Amita GuptaJohns Hopkins University School of Medicine, Baltimore, United States of America.
CTRIUMPH Study Team
Johns Hopkins University · USNational Institute of Research in Tuberculosis · INGovernment Medical College · INIndian Council of Medical Research · IN

Funding

The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
HIV-TB Fogarty Research Training ProgramD43TW009574 · FIC · JOHNS HOPKINS UNIVERSITY · PI BOLLINGER, ROBERT C. · 2013 to 2017
$1.0M
FIC NIH HHS D43 TW009574NIAID NIH HHS UM1 AI069465
6 · The paper itself

Abstract

backgroundWorld Health Organization (WHO) recommends systematic screening of high-risk populations, including household contacts (HHCs) of adult pulmonary tuberculosis (TB) patients, as a key strategy for elimination of TB. QuantiFERON-TB Gold In-Tube (QFT-GIT) assay and tuberculin skin test (TST) are two commonly used tools for the detection of latent tuberculosis infection (LTBI) but may yield differential results, affecting eligibility for TB preventive therapy. MATERIALS AND

methodsA prospective cohort study of adult pulmonary TB patients and their HHCs were recruited in 2 cities of India, Pune and Chennai. HHCs underwent QFT-GIT (QIAGEN) and TST (PPD SPAN 2TU/5TU). A positive QFT-GIT was defined as value ≥0.35 IU/ml and a positive TST as an induration of ≥5 mm. A secondary outcome of TST induration ≥10mm was explored. Proportion positive by either or both assays, discordant positives and negatives were calculated; test concordance was assessed using percentage agreement and kappa statistics; and risk factors for concordance and discordance including age categories were assessed using logistic regression. Sensitivity and specificity was estimated by latent class model.

resultsOf 1048 HHCs enrolled, 869 [median (IQR) age: 27 years (15-40)] had both TST and QFT-GIT results available and prevalence of LTBI by QFT-GIT was 54% [95% CI (51, 57)], by TST was 55% [95% CI (52, 58)], by either test was 74% [95% CI (71, 77) and by both tests was 35% [95% CI (31, 38)]. Discordance of TST+/QFT-GIT- was 21% while TST-/QFT-GIT+ was 26%. Poor to fair agreement occurred with TST 5mm or 10mm cutoff (60 and 61% agreement with kappa value of 0.20 and 0.25 respectively). Test agreement varied by age, TST strength and induration cut-off. In multivariate analysis, span PPD was a risk factor for QFT-GIT+ and TST- while absence of BCG scar was for TST+ and QFT-GIT-. Being employed and exposure to TB case outside the household case were associated with positivity by both the tests. Sensitivity of TST and QFT-GIT to diagnose LTBI was 77% and 69%. Probability of having LTBI was >90% when both tests were positive irrespective of exposure gradient.

conclusionPrevalence of LTBI among HHCs of adult pulmonary TB patients in India is very high and varies by test type, age, and exposure gradient. In our high TB burden setting, a strategy to treat all HHCs or a targeted strategy whereby an exposure index is used should be assessed in future preventive therapy and vaccine studies as HHCs have several factors that place them at high risk for progression to TB disease.

Indexed as

AdolescentAdultFemaleHumansIndiaLatent TuberculosisLogistic ModelsMalePrevalenceProspective StudiesRisk FactorsSensitivity and SpecificityTuberculin TestYoung Adult

Identifiers

PMID30067752
PMCPMC6070176
OpenAlexW2887933453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.